OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets cut its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 43.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,977 shares of the company’s stock after selling 1,494 shares during the period. BNP Paribas Financial Markets’ holdings in OrthoPediatrics were worth $46,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Invesco Ltd. increased its position in shares of OrthoPediatrics by 3.0% during the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company’s stock valued at $379,000 after acquiring an additional 469 shares during the last quarter. Northern Trust Corp grew its holdings in shares of OrthoPediatrics by 0.3% in the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company’s stock valued at $4,492,000 after purchasing an additional 644 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of OrthoPediatrics by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,411 shares of the company’s stock valued at $612,000 after purchasing an additional 1,042 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of OrthoPediatrics by 3.8% in the fourth quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company’s stock valued at $1,338,000 after purchasing an additional 2,099 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of OrthoPediatrics by 31.1% in the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company’s stock valued at $228,000 after purchasing an additional 2,338 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on KIDS shares. Piper Sandler dropped their price objective on shares of OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Thursday, May 8th. Stifel Nicolaus dropped their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Truist Financial dropped their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a report on Friday, April 11th. Lake Street Capital started coverage on shares of OrthoPediatrics in a report on Monday, April 7th. They issued a “buy” rating and a $37.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.83.

OrthoPediatrics Trading Up 2.4%

NASDAQ KIDS opened at $20.44 on Wednesday. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a 52 week low of $19.52 and a 52 week high of $35.99. The stock has a market capitalization of $496.43 million, a PE ratio of -16.62 and a beta of 1.09. The firm has a 50 day moving average of $21.91 and a two-hundred day moving average of $23.53.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.41 million for the quarter, compared to analyst estimates of $51.68 million. As a group, research analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Fred Hite sold 6,443 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $160,172.98. Following the completion of the sale, the chief financial officer now owns 207,989 shares in the company, valued at approximately $5,170,606.54. The trade was a 3.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David R. Bailey sold 6,620 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company’s stock, valued at $7,934,193.30. This represents a 2.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,732 shares of company stock worth $589,978 in the last 90 days. Corporate insiders own 32.70% of the company’s stock.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.